Lyme and Microencephaly- a true and proven association

Lyme and Microencephaly- a true and proven association

To: zerhoune@od.nih.gov, SpinLyme@yahoogroups,com ,
kshepard@calea.org, fitzmas@gmail,com , patrick.fitzgerald@usdoj.gov,
modelt1918@sbcglobal,net , jdrazen@nejm.org, letters@courant,com ,
Jgerberding@cdc.gov, lender@courant,com , michael.cole@po.state.ct.us,
conndcj@po.state.ct.us, executive-editor@nytimes,com , managing-
editor@nytimes,com , news-tips@nytimes,com , the-arts@nytimes,com ,
bizday@nytimes,com , foreign@nytimes,com , metro@nytimes,com ,
national@nytimes,com , dvbid@cdc.gov, brigidcallahan@optonline,net ,
trvl@hotmail,com , ubinas@courant,com , mas1@concentric,net ,
campbell@courant,com , jhornberger@fff.org, thomas.carson@usdoj.gov,
thomas.ryan@po.state.ct.us, kurtzh@washpost,com ,
georgewill@washpost,com , horgan@courant,com ,
commissioner.dcf@po.state.ct.us, cohencolumn@aol,com ,
FalNields@aol,com , bransfield@comcast,net , vtsherr@comcast,net ,
oca@po.state.ct.us, dand@davila-dilzer,com ,
scott.murphy@po.state.ct.us, governor.rell@po.state.ct.us,
attorney.general@po.state.ct.us, randall.samborn@usdoj.gov
Cc: francam@ucia.gov, dr-ahmadinejad@president.ir,
eugenerobinson@washpost,com , horgan@courant,com ,
bmiller@newstimes,com , trvl@hotmail,com , rastro18@aol,com ,
billcurryct@gmail,com , thomas.carson@usdoj.gov, amcguigan@rms-law,com ,
rjmurzyn@aol,com , paulcraigroberts@yahoo,com ,
sidney blumenthal@yahoo,com , criminal.division@usdoj.gov,
karla.dobinski@usdoj.gov, christopher.christie@usdoj.gov

Subject: COURANT: Drug companies' disclosure and Baxter's new OspA
vaccine

Date: Apr 11, 2008 5:41 AM

COURANT ARTICLE BELOW IS INCOMPLETE
========================================
Um, Lyme cabal members Gary Wormser and Allen Steere are paid
consultants for Baxter
who wants to produce a new tripartite OspA vaccine, when do to so,
clearly shows
intent to continue to define Lyme as an autoimmune arthritis in a
knee, when in
33 years, Allen Steere has yet to prove Lyme is an autoimmune
arthritis in a knee.
In fact, NINDS' Roland Martin went back to Germany because he was
unable to
prove the Multiple Sclerosis kind of Lyme (does not test positive,
since "CDC
positive" is the Steere genetically linked OspA hypersensitivity
reaction in
a knee), was an autoimmune T cell disease.

Steere not proving "Lyme disease" is an autoimmune arthritic disease:
http :// www .ncbi.nlm.nih.gov/pubmed/18191206?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed ResultsPanel.Pubmed RVDocSum
Martin not proving the former, pre-Dearborn kind of Lyme, is an
autoimmune neurologic
disease:
http :// www .ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&CmdÞtailsSearch&Term=(martin+r%5BAuthor%5D+OR+martin+r%5BInvestigator%5D)+AND+(%22borrelia%22%5BMeSH+Terms%5D+OR+Borrelia%5BText+Word%5D)
Steere and Wormser consulting for Baxter:
http :// www .actionlyme.org/WORMSER INSISTS LYME A KNEE DISEASE.htm
NIH's Edward McSweegan declaring that a new OspA vaccine would be
easier to
promote in Europe because Europeans are stupider than Americans:
http :// www .actionlyme.org/MCSWEEGAN AND DUMB EUROPEANS.html
What happened at Dearborn:
http :// www .actionlyme.org/CRYMEDISEASE CHP3.htm
(includes the CDC's final announcement with no bands OspA and B (31
and 34 kilodaltons
apparent weight)
Who Approved of this bogus standard despite none of the invited labs
agreeing:
http :// www .actionlyme.org/Dearborn Who Approved.htm
(McSweegan, Alan Barbour, and Allen Steere)
My explanation to the FDA vaccine committee that there was an older
CDC standard
for the diagnosis of Lyme that treated it as a Relapsing Fever
organism, and that
no one among the invited labs agreed with the cabal:
http :// www .actionlyme.org/DICKSON FDA SUBMISSION FULL.htm

The RICO complaint which makes the whole thing simpler and something
you can see
with your own eyeballs (darker bands means higher antibody
concentration consistent
with a hypersensitivity reaction, and not aberrant T cells, as Steere
proposes):
http :// www .actionlyme.org/USDOJ COMPLAINT RICO.htm
Steere's HLA:
http :// www .ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&CmdÞtailsSearch&Term=steere+AC%5BAuthor%5D+AND+HLA%5BAll+Fields%5D

I'll say it again, "Lyme Disease" - the new and bogus definition that
happened at Dearborn in order to falsely qualify LYMErix - is a
hypersensitivity
reaction or a condition of kinetics, where the antigen fits too
tightly in the Steere
HLA molecule and causes a toxic "complex."

It does not mean no infection and it does not mean infection, but as
we know with
other allergies, they go away when not exposed to the antigen any more
(seasonal
allergies).

IF, over time, autoimmune arthritis in a knee subsides, that could be
due to antigenic
variation, and the bugs are no longer making the kind of OspA that
"binds the
HLA molecule."

I would say it the other way around. The HLA molecule binds the
antigen, rather
than simply presenting it, as I demonstrate in the second RICO video:
http :// www .actionlyme.org/YOUTUBEVIDEOS.htm
with "Mr. Panda."


So, bottom line, Baxter is not listed here in this story and neither
is SmithKline.
The Lyme cabal at New York Medical College and Yale insist Lyme is an
"autoimmune
arthritis in a knee" and that "there is no such thing as the Roland
Martin,
National Institute of Neurological Disorders and Stroke kind of
Lyme." In
this way, these criminals can use the fact that the cabal invented
that there is
"no such thing as anything other than Lyme-as-a-bad-knee," because
they
are still being sued, after the two class actions against them.

If chronic and latent Lyme was the real disease we say it is - by re-
reporting these
crooks' own data - then it is something that could be activated by the
immune
suppressing qualities of OspA, which is a fungal antigen and known to
be immune
suppressing:
http :// www .actionlyme.org/BIOWEAPONEERS CORIXA YALE TLRS.htm

Here is proof that Yale et al know fungal antigens cause immune
suppression:
http :// www .pubmedcentral.nih.gov/picrender.fcgi?artid07827&blobtype=pdf

We're saying "Chronic Lyme" is the chronic infection that causes
immune
suppression diseases related outcomes, like the exacerbation of latent
viral infections
(causing MS), Lou Gehrig's Disease, Lupus, Chronic Fatigue Syndrome,
and the
ver-certain dementia like syphilis, as proven by these criminals
themselves, but
also, independent dental researchers:
http :// www .actionlyme.org/LYME IS A PERMANENT BRAIN INFECTION.htm


You can call the NIH and verify the Yale Lyme crooks' assertion that
Roland
Martin does not exist.... because he went back to Germany and you'd
have to
call there to talk to him about the MS kind of Lyme, or else view his
reports linked
from the right nav bar of my website, which I acquired by being "an
irresponsible
parent," by "going to the Yale Medical Library."
http :// www .actionlyme.org/Hilarious.htm

My sister, Nancy Martin, who is a genuine pinhead, does not like the
fact that I
am a scientist, because my father was an engineer. Don't expect that
to make
any sense, since we are talking about the "logic" that comes from a
very
small cranium. True Microencephaly.

Kathleen M. Dickson

=================================================courant,com /news/nationworld/ats-ap top13apr11,0,2546973.story
Courant,com
Drug Companies to Reveal Grant Practices

By KEVIN FREKING

Associated Press Writer

3:15 AM EDT, April 11, 2008

WASHINGTON

For years, the nation's largest drug and medical device manufacturers
have courted
doctors with consulting fees, free trips to exotic locales and by
sponsoring the
educational conferences that physicians attend.

Those financial ties don't have to be disclosed in most cases and can
lead to
arrangements that some say improperly influence medical care.

Now, under the threat of regulation from Congress, the two industries
promise to
be more forthcoming about their spending. A dozen of the nation's
leading drug
and device makers have told Sen. Charles Grassley, R-Iowa, that they
have plans
or are working on plans to publicly disclose grants to outside groups.
The details
will be provided on each company's Web sites.

Watchdog groups say the companies are trying to head off legislation
that would
require public disclosure of their giving.

"If they were doing this out of the goodness of their heart, they
would have
done so decades ago," said Dr. Peter Lurie of the consumer group
Public Citizen.

Of particular interest to Grassley is the money that companies spend
on continuing
medical education. Physicians go to such conferences to fulfill their
license requirements
and to keep up to date with the latest treatment trends. Professional
associations
and companies frequently ask drug and device makers to help pay for
the conferences.
Recently, Grassley asked 15 companies whether they planned to follow
the lead of
Eli Lilly & Co., which now discloses its grants to such programs.

"If your company does not yet have any efforts or plans in place,
please explain
why not," Grassley wrote.

The responses are in. They are wide-ranging, but mostly what the
senator wanted
to hear. Indeed, many of the companies said they would go beyond
disclosing grants
for medical education. Some companies said they would also disclose
payments to
patient advocacy groups such as the American Heart Association or the
American Diabetes
Association. Boston Scientific said it was developing a system that
even discloses
certain payments to physicians.

Medtronic Inc. said it will post payments for professional meetings
and patient
groups on its Web site beginning May 1. AstraZeneca PLC said it would
do the same
on Aug. 1, providing the amount spent and the purpose of the
financing. AstraZeneca
gets between 4,000 and 5,000 grant applications each year and funds
about a third
of them.

Merck and Co. was vague about its plans, but committed to the concept.
"We
are currently in the process of developing an action plan," the
company wrote
to Grassley.

Amgen Corp. and Abbott Laboratories said they had formed working
groups to determine
how to compile and display their grants.

Shering-Plough Corp., however, told the senator what he didn't want to
hear:
"We do not publish or have plans at the moment to publish a list of
charitable
contributions or educational grants that medical organizations have
received from
us."

Grassley said, overall, he was happy with the responses.

"The way these companies are making information about financial
relationships
open to scrutiny is the right thing to do," he said.

Two other companies said they already were disclosing third-party
payments. The
two, Zimmer Inc. and Stryker Orthopedics Inc., avoided criminal
prosecution over
financial inducements paid to surgeons to use their products,
prosecutors announced
last year. The companies agreed to new corporate compliance procedures
and federal
monitoring. Zimmer also had to pay the government $169.5 million.

The hip-and-knee industry was the subject of a recent Senate Aging
Committee hearing
titled "Surgeons for Sale." Companies routinely paid doctors $5,000
every
three months for providing information on market trends and operating-
room activity.
However, the reports typically offered only cursory descriptions and
often were
duplicated from one quarter to the next. Also, companies sponsored
consultant meetings
at resort locations. The meetings lasted just a few hours each day.
The physicians
who presented information at the meetings spoke for as little as 10
minutes.

"Although the remainder of the day was available for recreational
activities
paid for by the company, the consultants were compensated $5,000 for a
full day
of work," said Gregory E. Demske, an assistant inspector general.

Eli Lilly began listing its grants last year. It gave $18.9 million in
the second
quarter of 2007, according to the Prescription Policy Project, a
Boston-based group
that promotes policies to reduce conflicts of interest.

"They support those organizations which they believe will have a
positive impact
on their drug sales," said David Rothman of Columbia University and
associate
director of the Prescription Policy Project. "It's self-evident but
important."

If all of the companies follow through with their commitments to
Grassley, there
also would be widespread disclosure of how much money they give
patient advocacy
groups. The groups rely on industry for much of their financing. For
example, the
American Heart Association said donations from the pharmaceutical and
device industry
make up about 6 percent of its annual income, and totaled $48.3
million in the organization's
latest fiscal year.

"Donations from corporations, including the pharmaceutical and device
industry,
allow us to further enhance our programs and outreach, and to bring
objective science
and the highest quality of public education and information to more
people,"
said Maggie Francis, the association's communications manager.

Grassley and Sen. Herb Kohl, D-Wis., have introduced legislation that
would require
drug and device makers to disclose anything of value given to
physicians, such as
payments, gifts or travel.

The disclosure of medical education grants is an extension of that
concept. Last
year, the staff for the Senate Finance Committee issued a report that
said the drug
industry may be using the "medical education industry to deliver
favorable
messages about off-label uses that the drug companies cannot legally
deliver on
their own."

The committee report noted that Warner-Lambert, now owned by Pfizer
Inc., paid $430
million to settle claims that medical conferences it sponsored were
used to illegally
promote off-label uses of the anti-seizure drug Neurontin. Serono-
Laboratories paid
$704 million to settle a similar claim concerning the AIDS drug
Serostim.



On the Net:

Senate Finance Committee Report:

null

The Prescription Project: http :// www .prescriptionproject.org

Copyright 2008 Associated Press. All rights reserved. This material
may n